AxoGen (AXGN)
(Delayed Data from NSDQ)
$11.02 USD
+0.27 (2.51%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $11.04 +0.02 (0.18%) 6:22 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXGN 11.02 +0.27(2.51%)
Will AXGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AXGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXGN
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AXGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
Other News for AXGN
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Affirmed for AxoGen Amid Strong Q2 Performance and Positive Growth Outlook
AxoGen price target raised by $2 at Canaccord, here's why
AxoGen price target raised by $3 at JMP Securities, here's why
AxoGen Appoints New CEO and Board Chair for Strategic Renewal